Dementia prevention breakthrough? metformin and lifestyle combo tested in major trial

NCT ID NCT05109169

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial tests whether combining a diabetes drug (metformin) with an intensive lifestyle program—including diet, exercise, brain training, and health monitoring—can prevent cognitive decline in older adults at risk for dementia. Six hundred participants aged 60-79 with risk factors but no dementia will be randomly assigned to either the combined intervention or standard health advice. The study lasts two years and measures changes in memory, thinking speed, and daily function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
metformin
What this could lead to
If successful, this could point toward a practical, drug-plus-lifestyle strategy to reduce dementia risk in older adults.
What could go wrong
This is a Phase 2 trial, so it is still early. The combination may not prove more effective than lifestyle advice alone, and metformin can cause gastrointestinal side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COGNITIVE DECLINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction dementia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ageing Epidemiology Research Unit, Imperial College London

    London, W6 8RP, United Kingdom

  • Finnish Institute of Health and Welfare - THL

    Helsinki, FI-00271, Finland

  • Karolinska Institutet

    Solna, 171 64, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.